The therapeutic role of renin-angiotensin system blockers in obesity- related renal disorders

Current Clinical Pharmacology

Volumn 9, Issue 1, 2014, Pages 2-9

  Santos, Sérgio Henrique Sousa ^a,b,c   Simões e Silva, Ana Cristina ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Institute of Health Sciences   (Brazil)

^c UNIMONTES   (Brazil)

Author keywords

Adipokines; Angiotensin II; Angiotensin (1 7); Chronic kidney disease; Inflammation; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALDOSTERONE; ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GHRELIN; INSULIN; LEPTIN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; RENIN INHIBITOR; RESISTIN; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; VASOPRESSIN;

ALBUMINURIA; ALDOSTERONE RELEASE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE COURSE; DRUG MEGADOSE; ELECTROLYTE BALANCE; END STAGE RENAL DISEASE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; VASCULAR SMOOTH MUSCLE;

ADIPOKINES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HUMANS; KIDNEY DISEASES; OBESITY; RENIN-ANGIOTENSIN SYSTEM;

EID: 84894085935     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748847112079990050     Document Type: Review

References (104)

1. Calderon JL, Zadshir A, Norris K. A survey of kidney disease and risk-factor information on the World Wide Web. MedGenMed 2004; 6: 3.
2. Kim SR, Yoo JH, Song HC, et al. Relationship of visceral and subcutaneous adiposity with renal function in people with type 2 diabetes mellitus. Nephrol Dial Transplant 2011; 26: 3550-5.
3. Simoes e Silva AC, Flynn JT. The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol 2012; 27:1835-45.
4. Santos RA, Ferreira AJ. Angiotensin-(1-7) and the reninangiotensin system. Curr Opin Nephrol Hypertens 2007; 16: 122-8.
5. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue reninangiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807-25.
6. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9.
7. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-43.
8. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The reninangiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 302: H1219-30.
9. Ribeiro-Oliveira A Jr., Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simoes e Silva AC. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag 2008; 4: 787-803.
10. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-63.
11. Santos SH, Fernandes LR, Mario EG, et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008; 57: 340-7.
12. Santos SH, Braga JF, Mario EG, et al. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol 2010; 30: 953-61.
13. Mario EG, Santos SH, Ferreira AV, Bader M, Santos RA, Botion LM. Angiotensin-(1-7) Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes. Peptides 2012; 33: 174-7.
14. Liu C, Lv XH, Li HX, et al. Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes. Acta Diabetol 2012; 49(4): 291-9.
15. Santos SH, Fernandes LR, Pereira CS, et al. Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet. Regul Pept 2012; 178: 64-70.
16. Bilman V, Mares-Guia L, Nadu AP, et al. Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7). Peptides 2012; 37: 247-51.
17. Munoz MC, Giani JF, Burghi V, et al. The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7). Regul Pept 2012.
18. Ferreira AJ, Bader M, Santos RA. Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review. Expert Opin Ther Pat 2012; 22: 567-74.
19. Tabbi-Anneni I, Buchanan J, Cooksey RC, Abel ED. Captopril Normalizes Insulin Signaling and Insulin-Regulated Substrate Metabolism in Obese (ob/ob) Mouse Hearts. Endocrinology 2008.
20. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110: 1507-12.
21. Kyvelou SM, Vyssoulis GP, Karpanou EA, et al. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006; 47: 21-8.
22. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542-51.
23. Alfie J, Aparicio LS, Waisman GD. Current strategies to achieve further cardiac and renal protection through enhanced reninangiotensin-aldosterone system inhibition. Rev Recent Clin Trials 2011; 6: 134-46.
24. Santos EL, de Picoli Souza K, Guimaraes PB, et al. Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. Int Immunopharmacol 2008; 8: 247-53.
25. Simoes e Silva AC, Diniz JS, Pereira RM, Pinheiro SV, Santos RA. Circulating renin Angiotensin system in childhood chronic renal failure: marked increase of Angiotensin-(1-7) in end-stage renal disease. Pediatr Res 2006; 60: 734-9.
26. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454-70.
27. Ramirez LM. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. Am J Hypertens 2002; 15: 832-3.
28. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24: 261-71.
29. Tamura K, Tanaka Y, Tsurumi Y, et al. The role of angiotensin AT1 receptor-associated protein in renin-angiotensin system regulation and function. Curr Hypertens Rep 2007; 9: 121-7.
30. Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 2009; 32: 533-6.
31. Marrero MB, Fulton D, Stepp D, Stern DM. Angiotensin IIinduced insulin resistance and protein tyrosine phosphatases. Arterioscler Thromb Vasc Biol 2004; 24: 2009-13.
32. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006; 7: 3-14.
33. Carey RM, Padia SH. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 2008; 19: 84-7.
34. Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens 2006; 20: 101-8.
35. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-4.
36. Izzo JL Jr., Zion AS. Value of Angiotensin receptor blocker therapy in diabetes. J Clin Hypertens (Greenwich) 2011; 13: 290-5.
37. Chou CL, Lai YH, Lin TY, Lee TJ, Fang TC. Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats. Arch Med Sci 2011; 7: 882-8.
38. Abe M, Suzuki H, Okada K, et al. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. Heart Vessels 2012.
39. Mende CW. Application of direct renin inhibition to chronic kidney disease. Cardiovasc Drugs Ther 2010; 24: 139-49.
40. Chen YT, Yang WC, Tarng DC, et al. Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease. BMC Nephrol 2012; 13: 89.
41. Abdellatif AA. The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence. Expert Rev Cardiovasc Ther 2012; 10: 251-63.
42. Jadhav M, Yeola C, Zope G, Nabar A. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development. J Postgrad Med 2012; 58: 32-8.
43. Khadzhynov D, Slowinski T, Lieker I, et al. Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis. Clin Pharmacokinet 2012; 51: 661-9.
44. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-8.
45. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15: 2792-800.
46. Tesauro M, Canale MP, Rodia G, et al. Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. Cardiol Res Pract 2011; 2011: 653182.
47. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-56.
48. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995; 1: 1311-4.
49. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
50. Schwartz MW, Woods SC, Porte D Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-71.
51. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550-62.
52. Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246: 409-18.
53. Corsonello A, Perticone F, Malara A, et al. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects. Int J Obes Relat Metab Disord 2003; 27: 566-73.
54. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57-65.
55. Serradeil-Le Gal C, Raufaste D, Brossard G, et al. Characterization and localization of leptin receptors in the rat kidney. FEBS Lett 1997; 404: 185-91.
56. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]. Kidney Int 1999; 56: 860-72.
57. Papafragkaki DK, Tolis G. Obesity and renal disease: a possible role of leptin. Hormones (Athens) 2005; 4: 90-5.
58. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-7.
59. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-509.
60. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
61. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004; 53 (Suppl 1): S143-51.
62. Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-8.
63. Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005; 96: 946-51.
64. Yano Y, Hoshide S, Ishikawa J, et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J Clin Hypertens (Greenwich) 2007; 9: 775-82.
65. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-56.
66. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009; 76: 145-8.
67. Nogueiras R, Novelle MG, Vazquez MJ, Lopez M, Dieguez C. Resistin: regulation of food intake, glucose homeostasis and lipid metabolism. Endocr Dev 2010; 17: 175-84.
68. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-9.
69. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007; 156: 279-84.
70. Iqbal N, Seshadri P, Stern L, Loh J, Kundu S, Jafar T, Samaha FF. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci 2005; 9: 161-5.
71. Menzaghi C, Salvemini L, Fini G, et al. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS ONE 2012; 7: e38414.
72. Nehus E, Furth S, Warady B, Mitsnefes M. Correlates of Resistin in Children with Chronic Kidney Disease: The Chronic Kidney Disease in Children Cohort. J Pediatr 2012; 161(2): 276-80.
73. Yaturu S, Reddy RD, Rains J, Jain SK. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine 2007; 37: 1-5.
74. Axelsson J, Bergsten A, Qureshi AR, et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69: 596-604.
75. Baessler A, Hasinoff MJ, Fischer M, et al. Genetic linkage and association of the growth hormone secretagogue receptor (ghrelin receptor) gene in human obesity. Diabetes 2005; 54: 259-67.
76. Iantorno M, Chen H, Kim JA, et al. Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 2007; 292: E756-64.
77. Cano P, Cardinali DP, Rios-Lugo MJ, Fernandez-Mateos MP, Reyes Toso CF, Esquifino AI. Effect of a high-fat diet on 24-hour pattern of circulating adipocytokines in rats. Obesity (Silver Spring) 2009; 17: 1866-71.
78. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
79. Ohashi K, Ouchi N, Matsuzawa Y. Adiponectin and hypertension. Am J Hypertens 2011; 24: 263-9.
80. Lely AT, Krikken JA, Bakker SJ, et al. Low dietary sodium and exogenous angiotensin II infusion decrease plasma adiponectin concentrations in healthy men. J Clin Endocrinol Metab 2007; 92: 1821-6.
81. Simoes e Silva AC. Pathophysiology of Arterial Hypertension: Insights from Pediatric Studies. Curr Pediatric Rev 2006; 2(15): 209-23.
82. Song JH, Cha SH, Hong SB, Kim DH. Dual blockade of the reninangiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens Suppl 2006; 24: S101-6.
83. Simoes ESAC, Diniz JS, Regueira Filho A, Santos RA. The renin angiotensin system in childhood hypertension: selective increase of angiotensin-(1-7) in essential hypertension. J Pediatr 2004; 145: 93-8.
84. Kim SM, Jang HR, Lee YJ, et al. Urinary angiotensinogen levels reflect the severity of renal histopathology in patients with chronic kidney disease. Clin Nephrol 2011; 76: 117-23.
85. Crowley SD, Gurley SB, Oliverio MI, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest 2005; 115: 1092-9.
86. Hunley TE, Ma LJ, Kon V. Scope and mechanisms of obesityrelated renal disease. Curr Opin Nephrol Hypertens 2010; 19: 227-34.
87. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-74.
88. de Vinuesa SG, Goicoechea M, Kanter J, et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 2006; 17: S206-12.
89. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26: 3153-9.
90. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-6.
91. Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-7.
92. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 2005; 46: 587-94.
93. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
94. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 447-52.
95. Cohen P, Zhao C, Cai X, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001; 108: 1113-21.
96. Ryan AS, Berman DM, Nicklas BJ, et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 2003; 26: 2383-8.
97. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41: 625-33.
98. Hall JE, da Silva AA, do Carmo JM, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010; 285: 17271-6.
99. Rotimi C, Cooper R, Ogunbiyi O, et al. Hypertension, serum angiotensinogen, and molecular variants of the angiotensinogen gene among Nigerians. Circulation 1997; 95: 2348-50.
100. Pratt JH, Ambrosius WT, Tewksbury DA, Wagner MA, Zhou L, Hanna MP. Serum angiotensinogen concentration in relation to gonadal hormones, body size, and genotype in growing young people. Hypertension 1998; 32: 875-9.
101. Chou CL, Pang CY, Lee TJ, Fang TC. Direct renin inhibitor prevents and ameliorates insulin resistance, aortic endothelial dysfunction and vascular remodeling in fructose-fed hypertensive rats. Hypertens Res 2012.
102. Yildiz A, Hursit M, Celik AV, et al. Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. Clin Nephrol 2002; 58: 405-10.
103. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
104. David S, Kumpers P, Lukasz A, Kielstein JT, Haller H, Fliser D. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J Hypertens 2009; 27: 1641-7.